[
  {
    "ts": "2026-02-10T00:23:54+00:00",
    "headline": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
    "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "67b2f8ee-e066-32bb-a421-7d4a55fb3212",
      "content": {
        "id": "67b2f8ee-e066-32bb-a421-7d4a55fb3212",
        "contentType": "STORY",
        "title": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
        "pubDate": "2026-02-10T00:23:54Z",
        "displayTime": "2026-02-10T00:23:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T09:10:00+00:00",
    "headline": "Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?",
    "summary": "The stock has climbed in the triple digits over the past three years.",
    "url": "https://www.fool.com/investing/2026/02/10/could-eli-lilly-turn-todays-glp1-obesity-boom-into/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "65cdd472-6bbe-3900-ba83-d77d0c3c534a",
      "content": {
        "id": "65cdd472-6bbe-3900-ba83-d77d0c3c534a",
        "contentType": "STORY",
        "title": "Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?",
        "description": "",
        "summary": "The stock has climbed in the triple digits over the past three years.",
        "pubDate": "2026-02-10T09:10:00Z",
        "displayTime": "2026-02-10T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3575ec1d5e649814f22b2c433c57d1da",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor smiles while looking at something on a phone.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iIZVKjYYT59JuL3mi9iIrQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3575ec1d5e649814f22b2c433c57d1da.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O2.JzyyIdj5T4__W1T8oMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3575ec1d5e649814f22b2c433c57d1da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/could-eli-lilly-turn-todays-glp1-obesity-boom-into/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/could-eli-lilly-turn-todays-091000394.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T05:01:00+00:00",
    "headline": "Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs",
    "summary": "Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.",
    "url": "https://www.thedailyupside.com/industries/healthcare/novo-nordisk-launches-suit-to-knock-out-hims-hers-weight-loss-knockoffs/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "389b6907-4e58-3613-a557-2518d1652653",
      "content": {
        "id": "389b6907-4e58-3613-a557-2518d1652653",
        "contentType": "STORY",
        "title": "Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs",
        "description": "",
        "summary": "Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.",
        "pubDate": "2026-02-10T05:01:00Z",
        "displayTime": "2026-02-10T05:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/cc9fcb1ff5ae299bf83351d83efba856",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of Novo Nordisk CEO Mike Doustdar.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H6m4g3K9D__F0B_UM7qnbw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/cc9fcb1ff5ae299bf83351d83efba856.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Oi09qg9f1oDO_3C0sotpQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/cc9fcb1ff5ae299bf83351d83efba856.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/novo-nordisk-launches-suit-to-knock-out-hims-hers-weight-loss-knockoffs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-launches-suit-knock-050100057.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "KR"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T14:35:00+00:00",
    "headline": "Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.",
    "summary": "Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?",
    "url": "https://www.fool.com/investing/2026/02/10/eli-lilly-is-partnering-with-gene-editing-start-up/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7b8152d5-3599-3fb9-ac4a-992668716cf4",
      "content": {
        "id": "7b8152d5-3599-3fb9-ac4a-992668716cf4",
        "contentType": "STORY",
        "title": "Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.",
        "description": "",
        "summary": "Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?",
        "pubDate": "2026-02-10T14:35:00Z",
        "displayTime": "2026-02-10T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/51e174e39ebb12921e94819c96cc931e",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "A person using an injection pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BJSPhZ0KEwr.zucNuPUtBw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/51e174e39ebb12921e94819c96cc931e.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nbma.1IT0jIgKwinqodXGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/51e174e39ebb12921e94819c96cc931e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/eli-lilly-is-partnering-with-gene-editing-start-up/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-partnering-gene-editing-143500070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T16:10:00+00:00",
    "headline": "LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal",
    "summary": "Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.",
    "url": "https://finance.yahoo.com/news/lly-expands-cell-therapy-ambitions-161000480.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "7e5238de-6019-3dc6-b406-9d8dfe2e03d0",
      "content": {
        "id": "7e5238de-6019-3dc6-b406-9d8dfe2e03d0",
        "contentType": "STORY",
        "title": "LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal",
        "description": "",
        "summary": "Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.",
        "pubDate": "2026-02-10T16:10:00Z",
        "displayTime": "2026-02-10T16:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lly-expands-cell-therapy-ambitions-161000480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lly-expands-cell-therapy-ambitions-161000480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T15:49:00+00:00",
    "headline": "Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026",
    "summary": "LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with EPS up over 40% in 2026.",
    "url": "https://finance.yahoo.com/news/eli-lillys-2025-surge-sets-154900858.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "fbe2c143-2d31-3a18-b388-31f3aa61a036",
      "content": {
        "id": "fbe2c143-2d31-3a18-b388-31f3aa61a036",
        "contentType": "STORY",
        "title": "Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026",
        "description": "",
        "summary": "LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with EPS up over 40% in 2026.",
        "pubDate": "2026-02-10T15:49:00Z",
        "displayTime": "2026-02-10T15:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/44fc6e96ff9dff6be2f033510781bcfa",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mUTJIX7OAIF4t_2K4liGgg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/44fc6e96ff9dff6be2f033510781bcfa.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/THmx2aF2GIf5jYYaguFdlw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/44fc6e96ff9dff6be2f033510781bcfa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lillys-2025-surge-sets-154900858.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lillys-2025-surge-sets-154900858.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T15:38:00+00:00",
    "headline": "INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales",
    "summary": "Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.",
    "url": "https://finance.yahoo.com/news/incy-q4-earnings-miss-estimates-153800997.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "7f9760be-9de3-3fbc-a415-de227c45d2f1",
      "content": {
        "id": "7f9760be-9de3-3fbc-a415-de227c45d2f1",
        "contentType": "STORY",
        "title": "INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales",
        "description": "",
        "summary": "Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.",
        "pubDate": "2026-02-10T15:38:00Z",
        "displayTime": "2026-02-10T15:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/57.Lfvcoa8N_9pHFAUTShA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/39hBnd4FwGlouiqapgQKxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incy-q4-earnings-miss-estimates-153800997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incy-q4-earnings-miss-estimates-153800997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T12:13:00+00:00",
    "headline": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
    "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
    "url": "https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-eczema-maintenance-data-results/811806/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "6994b182-57ca-3e3a-b0ac-5726fb73a6f6",
      "content": {
        "id": "6994b182-57ca-3e3a-b0ac-5726fb73a6f6",
        "contentType": "STORY",
        "title": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
        "description": "",
        "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
        "pubDate": "2026-02-10T12:13:00Z",
        "displayTime": "2026-02-10T12:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/ab0100ff22dcd604e28e26f63b7e28a0",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5v2gYUHyJ1AR46sVYpqIHA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/ab0100ff22dcd604e28e26f63b7e28a0.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dkwf9lKXNHro10yfUo.ahA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/ab0100ff22dcd604e28e26f63b7e28a0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-eczema-maintenance-data-results/811806/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nektar-continuing-comeback-says-eczema-121300710.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NKTR"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T21:51:00+00:00",
    "headline": "Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway.",
    "summary": "Less than two months into 2026, shares of  Gilead Sciences  are already outpacing some of the most talked-about pharmaceutical companies.  After the closing bell, the biopharmaceutical company posted adjusted earnings of $1.86 a share, which outstripped analysts’ calls for $1.81.  Gilead attributed the change to higher sales of HIV and liver-disease products, which were partially offset by lower sales of Veklury, its Covid-19 antiviral.",
    "url": "https://www.barrons.com/articles/gilead-earnings-stock-price-f1f36bf5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8a748589-aea8-3e07-a0d3-cb4d585b2ae3",
      "content": {
        "id": "8a748589-aea8-3e07-a0d3-cb4d585b2ae3",
        "contentType": "STORY",
        "title": "Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway.",
        "description": "",
        "summary": "Less than two months into 2026, shares of  Gilead Sciences  are already outpacing some of the most talked-about pharmaceutical companies.  After the closing bell, the biopharmaceutical company posted adjusted earnings of $1.86 a share, which outstripped analysts’ calls for $1.81.  Gilead attributed the change to higher sales of HIV and liver-disease products, which were partially offset by lower sales of Veklury, its Covid-19 antiviral.",
        "pubDate": "2026-02-10T21:51:00Z",
        "displayTime": "2026-02-10T21:51:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8a748589-aea8-3e07-a0d3-cb4d585b2ae3/gilead-earnings-surprise-why.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X078vvJXUIiLEBq8utnocA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cpMrX8Jl6P9ldyk1tq3_og--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/gilead-earnings-stock-price-f1f36bf5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]